type 2 diabetic patients with coronary artery disease
Conditions
Interventions
group A: additive therapy of ipragliflozin 50-100mg once daily to DPP4 inhibitor for 6 months
Group B: additive therapy of metformin 250-750mg twice daily to DPP4 inhibitor for 6 months
Sponsors
Anjo Kosei Hospital, Cardiovascular Center
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1) Patients who have a history of following coronary heart diseasese CABG or PCI was performed more than 6 months before >= 50% coronary artery stenosis according to the ACC/AHA classification was found by CAG 2) Diabetic patients under treatment of DPP-4 inhibitor more than 3 months 3) Patients who are judged to require the more glucose-lowering therapy
Exclusion criteria
Exclusion criteria: 1) Patients with malignancy 2) Patients with history of hypersensitivity against DPP4 inhibitor, SGLT2 inhibitor, and biguanide drugs 3) patients whose glycemic control is extremely poor (HbA1c >=10%) 4) patients whose glycemic control is very poor (HbA1c >=10%) 5) Pregnant women, women who may be pregnant, and breast-feeding women. 6) Patients with history of renal transplantation, urinary infection, sexually transmission disease, and non-cardiogenic stroke 7) Patients who took diuretics 8) patients whose BMI is lower than 18.5 9) Patients with history of acute coronary syndrome within 6 months 10) Patients judged by the investigator/ sub investigator to be ineligible for some other reason
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Changes in adipocytokine | — |
Secondary
| Measure | Time frame |
|---|---|
| Changes in glucose metabolism Changes in body weight and abdominal circumference Changes in laboratory parameters Assessment of vascular event | — |
Countries
Japan
Contacts
Public ContactYusuke Uemura
Anjo Kosei Hospital cardiovascular Center
Outcome results
None listed